Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 6/2008

01-06-2008 | Original Article

Dissection and molecular analysis of alloreactive CD8+ T cell responses in allogeneic haematopoietic stem cell transplantation

Authors: Catherine Wölfel, Volker Lennerz, Eva Lindemann, Georg Hess, Hans G. Derigs, Christoph Huber, Wolfgang Herr, Thomas Wölfel

Published in: Cancer Immunology, Immunotherapy | Issue 6/2008

Login to get access

Abstract

We applied a cDNA expression screening procedure with cryopreserved non-clonal CD8+ T cell populations (Lennerz et al., Proc. Natl. Acad. Sci. USA 102:16013-8, 2005) to the identification of candidate antigens for graft-versus-host disease (GvHD) and graft-versus-leukaemia (GvL) effects in allogeneic haematopoietic stem cell transplantation (allo-HSCT). In a patient–donor model system with HLA class I disparities, we identified an HLA-B*44 mismatch allele, HLA-B*4405, as the dominant target of alloreactive T cells expanded in vitro from donor peripheral blood mononuclear cells (PBMC). HLA-B*4405-reactive T cells were detectable after multiple in vitro stimulations in the patient’s post-HSCT PBMC. In a patient–donor model with full HLA compatibility, the major target antigen of donor lymphocytes stimulated in vitro with the respective patient’s pre-HSCT PBMC was restricted by HLA-A*0201 and was encoded by TRIM22-442 C, a newly detected polymorphic allele of the tripartite motif family member TRIM22 (synonym: STAF50), preferentially expressed in cells of the haematopoietic system. An arginine(R)-to-cysteine(C) exchange at position 442 generated an immunogenic T cell epitope equivalent to a minor histocompatibility antigen (mHag). TRIM22-442C-specific T cells persisted long-term in the patient’s post-HSCT PBMC. Approximately, 1.3% of Caucasians carry TRIM22.442 C in association with HLA-A*0201. In particular, the knowledge of a large and diverse panel of such mHags may be crucial for further improvement of donor selection and adoptive T cell transfer strategies. The procedure applied herein will help to accelerate and facilitate their identification.
Literature
1.
go back to reference Apperley JF, Jones L, Hale G, Waldmann H, Hows J, Rombos Y et al (1986) Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1:53–66PubMed Apperley JF, Jones L, Hale G, Waldmann H, Hows J, Rombos Y et al (1986) Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1:53–66PubMed
2.
go back to reference Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A (1978) Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens: new tools for genetic analysis. Cell 14:9–20PubMedCrossRef Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A (1978) Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens: new tools for genetic analysis. Cell 14:9–20PubMedCrossRef
3.
go back to reference Britten CM, Meyer RG, Kreer T, Drexler I, Wolfel T, Herr W (2002) The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. J Immunol Methods 259:95–110PubMedCrossRef Britten CM, Meyer RG, Kreer T, Drexler I, Wolfel T, Herr W (2002) The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. J Immunol Methods 259:95–110PubMedCrossRef
4.
go back to reference Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ (1984) The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 38:287–292PubMedCrossRef Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ (1984) The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 38:287–292PubMedCrossRef
5.
go back to reference den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL et al (1998) The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279:1054–1057CrossRef den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL et al (1998) The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279:1054–1057CrossRef
6.
go back to reference Ennis PD, Zemmour J, Salter RD, Parham P (1990) Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction: frequency and nature of errors produced in amplification. Proc Natl Acad Sci USA 87:2833–2837PubMedCrossRef Ennis PD, Zemmour J, Salter RD, Parham P (1990) Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction: frequency and nature of errors produced in amplification. Proc Natl Acad Sci USA 87:2833–2837PubMedCrossRef
7.
go back to reference Fleischhauer K, Kernan NA, O’Reilly RJ, Dupont B, Yang SY (1990) Bone marrow allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. N Engl J Med 323:1818–1822PubMedCrossRef Fleischhauer K, Kernan NA, O’Reilly RJ, Dupont B, Yang SY (1990) Bone marrow allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. N Engl J Med 323:1818–1822PubMedCrossRef
8.
go back to reference Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C (2001) Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med 7:789–794PubMedCrossRef Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C (2001) Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med 7:789–794PubMedCrossRef
9.
go back to reference Goulmy E (2006) Minor histocompatibility antigens: from transplantation problems to therapy of cancer. Hum Immunol 67:433–438PubMedCrossRef Goulmy E (2006) Minor histocompatibility antigens: from transplantation problems to therapy of cancer. Hum Immunol 67:433–438PubMedCrossRef
10.
go back to reference Griem P, Wallny HJ, Falk K, Rotzschke O, Arnold B, Schonrich G, Hammerling G, Rammensee HG (1991) Uneven tissue distribution of minor histocompatibility proteins versus peptides is caused by MHC expression. Cell 65:633–640PubMedCrossRef Griem P, Wallny HJ, Falk K, Rotzschke O, Arnold B, Schonrich G, Hammerling G, Rammensee HG (1991) Uneven tissue distribution of minor histocompatibility proteins versus peptides is caused by MHC expression. Cell 65:633–640PubMedCrossRef
11.
go back to reference Kawase T, Morishima Y, Matsuo K, Kashiwase K, Inoko H, Saji H et al (2007) High-risk HLA allele mismatch combinations responsible for severe acute graft versus host disease and implication for its molecular mechanism. Blood 110(7):2235–2241PubMedCrossRef Kawase T, Morishima Y, Matsuo K, Kashiwase K, Inoko H, Saji H et al (2007) High-risk HLA allele mismatch combinations responsible for severe acute graft versus host disease and implication for its molecular mechanism. Blood 110(7):2235–2241PubMedCrossRef
12.
go back to reference Keever CA, Leong N, Cunningham I, Copelan EA, Avalos BR, Klein J et al (1994) HLA-B44-directed cytotoxic T cells associated with acute graft-versus-host disease following unrelated bone marrow transplantation. Bone Marrow Transplant 14:137–145PubMed Keever CA, Leong N, Cunningham I, Copelan EA, Avalos BR, Klein J et al (1994) HLA-B44-directed cytotoxic T cells associated with acute graft-versus-host disease following unrelated bone marrow transplantation. Bone Marrow Transplant 14:137–145PubMed
13.
go back to reference Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465PubMed Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465PubMed
14.
go back to reference Lemonnier FA, Rebai N, Le BP, Malissen B, Caillol DH, Kourilsky FM (1982) Epitopic analysis of detergent-solubilized HLA molecules by solid-phase radioimmunoassay. J Immunol Methods 54: 9–22PubMedCrossRef Lemonnier FA, Rebai N, Le BP, Malissen B, Caillol DH, Kourilsky FM (1982) Epitopic analysis of detergent-solubilized HLA molecules by solid-phase radioimmunoassay. J Immunol Methods 54: 9–22PubMedCrossRef
15.
go back to reference Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D et al (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102:16013–16018PubMedCrossRef Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D et al (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102:16013–16018PubMedCrossRef
16.
go back to reference Macdonald WA, Purcell AW, Mifsud NA, Ely LK, Williams DS, Chang L et al (2003) A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition. J Exp Med 198:679–691PubMedCrossRef Macdonald WA, Purcell AW, Mifsud NA, Ely LK, Williams DS, Chang L et al (2003) A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition. J Exp Med 198:679–691PubMedCrossRef
17.
go back to reference McMichael AJ, Parham P, Rust N, Brodsky FM (1980) A monoclonal antibody that recognizes an antigenic determinant shared by HLA-A2 and B17. Hum Immunol 1:121–129PubMedCrossRef McMichael AJ, Parham P, Rust N, Brodsky FM (1980) A monoclonal antibody that recognizes an antigenic determinant shared by HLA-A2 and B17. Hum Immunol 1:121–129PubMedCrossRef
18.
go back to reference Nisole S, Stoye JP, Saib A (2005) TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3:799–808PubMedCrossRef Nisole S, Stoye JP, Saib A (2005) TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3:799–808PubMedCrossRef
19.
go back to reference Obad S, Brunnstrom H, Vallon-Christersson J, Borg A, Drott K, Gullberg U (2004) Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells. Oncogene 23:4050–4059PubMedCrossRef Obad S, Brunnstrom H, Vallon-Christersson J, Borg A, Drott K, Gullberg U (2004) Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells. Oncogene 23:4050–4059PubMedCrossRef
20.
go back to reference Obad S, Olofsson T, Mechti N, Gullberg U, Drott K (2007) Expression of the IFN-inducible p53-target gene TRIM22 is down-regulated during erythroid differentiation of human bone marrow. Leuk Res 31:995–1001PubMedCrossRef Obad S, Olofsson T, Mechti N, Gullberg U, Drott K (2007) Expression of the IFN-inducible p53-target gene TRIM22 is down-regulated during erythroid differentiation of human bone marrow. Leuk Res 31:995–1001PubMedCrossRef
21.
go back to reference Peggs K, Verfuerth S, Pizzey A, Ainsworth J, Moss P, Mackinnon S (2002) Characterization of human cytomegalovirus peptide-specific CD8(+) T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cells. Blood 99:213–223PubMedCrossRef Peggs K, Verfuerth S, Pizzey A, Ainsworth J, Moss P, Mackinnon S (2002) Characterization of human cytomegalovirus peptide-specific CD8(+) T-cell repertoire diversity following in vitro restimulation by antigen-pulsed dendritic cells. Blood 99:213–223PubMedCrossRef
22.
go back to reference Petersdorf EW, Gooley T, Malkki M, Horowitz M (2007) Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens 69(Suppl 1):25–30PubMedCrossRef Petersdorf EW, Gooley T, Malkki M, Horowitz M (2007) Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens 69(Suppl 1):25–30PubMedCrossRef
23.
go back to reference Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L et al (2001) The tripartite motif family identifies cell compartments. Embo J 20:2140–2151PubMedCrossRef Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L et al (2001) The tripartite motif family identifies cell compartments. Embo J 20:2140–2151PubMedCrossRef
24.
go back to reference Slifka MK, Whitton JL (2001) Functional avidity maturation of CD8+ T cells without selection of higher affinity TCR. Nat Immunol 2:711–717PubMedCrossRef Slifka MK, Whitton JL (2001) Functional avidity maturation of CD8+ T cells without selection of higher affinity TCR. Nat Immunol 2:711–717PubMedCrossRef
25.
go back to reference Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L et al (1989) Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720–1728PubMed Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L et al (1989) Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720–1728PubMed
26.
go back to reference Thammavongsa V, Raghuraman G, Filzen TM, Collins KL, Raghavan M (2006) HLA-B44 polymorphisms at position 116 of the heavy chain influence TAP complex binding via an effect on peptide occupancy. J Immunol 177:3150–3161PubMed Thammavongsa V, Raghuraman G, Filzen TM, Collins KL, Raghavan M (2006) HLA-B44 polymorphisms at position 116 of the heavy chain influence TAP complex binding via an effect on peptide occupancy. J Immunol 177:3150–3161PubMed
27.
go back to reference Tissot C, Mechti N (1995) Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression. J Biol Chem 270:14891–14898PubMedCrossRef Tissot C, Mechti N (1995) Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression. J Biol Chem 270:14891–14898PubMedCrossRef
28.
go back to reference Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN (2001) Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98:49–56PubMedCrossRef Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN (2001) Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98:49–56PubMedCrossRef
Metadata
Title
Dissection and molecular analysis of alloreactive CD8+ T cell responses in allogeneic haematopoietic stem cell transplantation
Authors
Catherine Wölfel
Volker Lennerz
Eva Lindemann
Georg Hess
Hans G. Derigs
Christoph Huber
Wolfgang Herr
Thomas Wölfel
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 6/2008
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-007-0421-1

Other articles of this Issue 6/2008

Cancer Immunology, Immunotherapy 6/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine